The US Centers for Medicare and Medicaid Services (CMS) has been more restrictive in its national coverage policies affecting medical devices compared to those targeting drugs and biologics, according to a study that researchers say offers insight into the nascent FDA-CMS parallel review program.
Three researchers at Tufts University’s Center for the Evaluation of Value and Risk in Health analyzed data from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?